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The compound 1, [(1H-[1]benzoxepino[5,4-c]pyrazole-3-carboxamide, 8-chloro-1-(2,4-dichlorophenyl)-4,5-dihydro-N-
1-piperidinyl], a known CB1 modulator has been synthesized and characterized by IR, NMR and single Crystal X-ray study.
The single crystal study of 1 displays a number of halogen bonds leading to 1-D network along with other weak non-
covalent interactions. The CB1 modulator 1 inherently possesses extremely low solubility in water, which makes its
application as drug difficult, and this may be attributed to multiple halogen bonds present in the crystal structure. A series of
polymer additives, which are Generally Regarded As Safe (GRAS), have been explored to investigate whether they can
modulate the halogen bond present in 1 through formation of various non-bonded interactions. Surprisingly, these polymers
are found to change crystal morphology, crystal packing while retaining efficacy and bioavailability. The polymer molecular
weight is found to play a significant role in crystal morphology modification especially in case of polyethylene glycol
(PEG). The formation of new polymorphic forms of 1 and modification of halogen bond has been established using powder
X-ray diffraction and IR study, respectively, in case of PEG 4000, PVPK-30, PVA polymers and compound 1 adducts.
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Obesity, a lifestyle disease, is one of the largest and 
fastest growing public health problems in the 
developed and developing world1. Obesity is 
associated with substantial increases in morbidity, 
premature mortality, impaired quality of life and large 
healthcare costs2,3. Despite continuous effort and 
research, obesity pharmacotherapy has yielded very 
little success. Another approach to treat obesity is to 
regulate the appetite and food intake in animals and 
humans. A class of compounds, which have been 
evaluated for the regulation of appetite and food 
intake in animals and humans, are the cannabinoid 
receptor modulators (CB1 receptor modulators). 
Numerous drugs such as Rimonabant hydrochloride, 
Taranabant, Otenabant, Surinabant and Ibipinabant 
were developed as potential drugs targeting the 
cannabinoid receptor type 1 (CB1)4. Of these, 
Rimonabant was approved by the European 
Medicines Authority (EMA). However reports of 
serious psychiatric problems (such as anxiety, 
depression and suicide) led to its withdrawal from the 
market5-7. Despite the withdrawal of several CB1-
receptor-antagonist drugs from the market, many 
researchers believe that neutral antagonists might 
retain the weight loss advantages, but will be devoid 
of reported adverse effects8. Understandably, the 
promising approach is to develop agents, preferable 
without charge, to prevent it to cross the blood-brain 
barrier9. It is postulated that the excessive presence of 
such drug in brain may leads to many serious 
psychiatric problems. One such promising CB1 
modulator is compound (1) [(1H-[1]benzoxepino[5,4-c] 
pyrazole-3-carboxamide, 8-chloro-1-(2,4-dichloro- 
phenyl)-4,5-dihydro-N-1-piperidinyl, with an EC50  
14.5 µM in human CB1 receptor forskolin-induced 
cAMP assay10.The compound 1 was expected to be a 
neutral antagonist since it did not change the 
forskolin-stimulated cAMP accumulation in CB1-
transfected HEK cells up to 10 µM concentration. 
Therefore, the compound 1 has a great potential for 




the treatment of obesity. Unfortunately, the crystalline 
form of the molecule suffers from poor oral 
bioavailability and pharmacokinetic profile11. The 
authors have earlier reported a process for the 
preparation of compound 1 in amorphous form11.  
A well-established approach to change the 
bioavailability and efficacy of a drug is the formation 
of salts/co-crystals, which is not suitable for the 
present study as formation of charged species should 
be avoided to deter the transportation of drug through 
blood-brain barrier. Therefore, a different approach is 
required to improve the physico-chemical properties 
of compound 1 without bringing any significant 
change to either its bio-availability or efficacy 
(Figure 1). 
For years, controlling the physical properties of 
solid APIs through modification of the solid phase 
without changing the molecular structure of the API 
itself has remained a prime research interest of 
academic and industrial research groups12,13. One of 
the most important and most used methods of non-
covalent modification of APIs is salt formation, in 
which the API is neutralized by an acid or a base to 
make a salt14. More recently, co-crystallization 
(broadly defined as the crystallization of two non-
covalently interacting neutral compounds in the same 
crystal lattice) has also been used for this purpose15,16. 
Co-crystallization has even more scope than salt 
formation because there appears to be no theoretical 
limit on the types of APIs that can be incorporated 
into co-crystals. Researchers have been able to make 
new co-crystals year after year17by combining design 
strategies such as the concepts of supramolecular 
synthons with high throughput screening methods 
such as solvent-assisted grinding. 
The synthesis of inorganic and organic materials 
with a specific size and morphology has recently 
received much attention in the material science 
research area. Many routes have been reported to 
control the crystal growth and eventually modify the 
morphology of the crystals. For crystal-habit 
modification, crystals are grown in the presence of 
naturally occurring soluble additives, which usually 
adsorb or bind to the crystal faces and influence the 
crystal growth or morphology18. 
Crystal growth modifiers can be used to achieve a 
range of outcomes. They can dramatically affect 
particle shape and size and therefore can be used in a 
particle engineering sense, i.e. to obtain the desired 
physical properties of the particles in question. 
Additives can also inhibit nucleation and growth 
which has applications such as scale inhibition. They 
may even increase the rate of crystallization and be 
used as promoters19. 
The crystal-habit modifiers may be of a very 
diverse nature, such as multivalent cations, 
complexes, surface active agents, soluble polymers, 
biologically active macromolecules, fine particles of 
sparingly soluble salts, and so on. These crystal 
modifiers often adsorb selectively on to different 
crystal faces and retard their growth rates, thereby 
influencing the final morphology of the crystals. The 
strategy uses organic additives and/or templates with 
complex functionalization patterns to control the 
nucleation, growth, and alignment of inorganic and 
organic crystals20. 
In the present study, we decided to address few 
questions related with compound 1 such as why 
compound 1 has very low bioavailability and what are 
the factors which influence the overall packing of 1 
leading to its inflexible behavior to form different 
crystalline forms. Efforts were also directed to 
understand the packing of compound 1 with respect to 
its various non-covalent interactions present in 
crystalline state, namely, halogen bond and 
amide…amide linkage and look for the methods to 
influence it. In this regards, we decided to study the 
effect of hydrophilic polymers as additive to 
compound 1, which can influence the amide…amide 
non-covalent interaction and Cl….Cl ( halogen bond) 
by giving additional possibilities of weak non-
covalent interactions such as Cl…O, O-H…O, etc. 
These polymers belong to the GRAS class of 
polymers and are used extensively in formulation 
studies. 
However, to the best of our knowledge such 
polymer additives have not been used to bring a 
 
 
Figure 1 — CB1 inhibitor used for the present study 




change to crystalline packing and crystal habit 
modification, simultaneously. In the present work, 
various GRAS polymer additives such as PVA, PEG 
and PVP K30, having different molecular weights 
were used for attempting to change the crystal 
packing, morphology and maintain the efficacy of 





The compound 1 was prepared as per process 
described earlier11. The polymers used in the present 
studies were purchased from Sigma-Aldrich, India. 
Analytical grade solvents were purchased from local 





Thermal analyses of all the compounds were 
carried out to understand the phase transition and 
stability of compound 1 with or without polymeric 
additives. The DSC (Differential Scanning 
Calorimeter) (Perkin Elmer Model Pyris 1) was used 
for all the thermal analysis. In a typical analysis, 2 mg 
to 3 mg of sample was taken in a clean aluminium pan 
and sealed under inert environment. The heating was 
done from an initial temperature of 50 °C and the 
temperature was gradually raised at a heating rate of 
10°C /min till 300 °C. Nitrogen gas was used at a 
flow rate of 20 ml/min. 
 
Powder X-ray Diffraction measurement (PXRD) 
Method 
Powder diffractionmeasurement was carried out on 
X-ray diffractometer (Rigaku make MF2100) using 
copper source at 40KV and 30 mA having Ni Kβ 
filter. The 2θ scan of each sample was carried out 
between 2-40° at scan speed of 4.0° per minute. 
 
Single crystal X-ray studies 
Crystal suitable for Single crystal X-ray study of 
compound 1 was obtained from acetone by slow 
evaporation method at room temperature. Diffraction 
data for 1 was collected using MoKα (λ = 0.71073 Å) 
radiation on Xcalibur, Eos, Gemini diffractometer. 
Structure of 1 was solved and refined using the Olex 
2 software21,22 and ShelXL23 refinement package. 
Graphics were generated using MERCURY 3.9. The 
structure was solved by direct methods and refined in 
a routine manner. In all cases, non-hydrogen atoms 
were treated anisotropically. Whenever possible, the 
hydrogen atoms were located on a difference Fourier 
map and refined in routine manner. In other cases, the 
hydrogen atoms were geometrically fixed. 
 
Scanning electron microscopy (SEM) 
The surface morphology of the respective samples 
was examined under ZEISS, EVO 18, scanning 
electron microscopy (SEM). Solid samples were 
evenly dispersed on small segment of microscopic 
glass slide. Then, they were kept in vacuum 
desiccators for ~1.5 h and the samples were attached 
to aluminum sample stubs using double-sided carbon 
tape and were coated with gold in a sputter coater and 
observed under SEM at an accelerating voltage of  
15 kV. Average diameters were measured on at least 
25 randomly chosen crystals at several regions of the 
samples. 
 
Preparation of crystals of compound 1 with  
PEG-200 (1A) 
Placed 0.500 g (1.017 mmol) of compound 1 in a 
round bottomed flask, to it was added 5 ml acetone. 
The suspension was warmed upto 45-50°C in a water 
bath to get clear solution. To it was added a solution 
of 20% PEG 200 in acetone (5 ml). The mixture was 
cooled and left to ambient conditions. Crystals were 
obtained as colourless blocks after two days, which 
were separated by filtration. 
 
Preparation of crystals of compound 1 with  
PEG-300 (1B) 
Placed 0.500 g (1.017 mmol) of compound 1 in a 
round bottomed flask, to it was added 5 ml acetone. 
The suspension was warmed upto 45-50°C in a water 
 
 
Figure 2 — List of polymers used as crystal habit modifier in the present study 




bath to get clear solution. To it was added a solution 
of 20% PEG 300 in acetone (10 ml). The mixture was 
cooled and left to ambient conditions. Crystals were 
obtained as colourless blocks after four days, which 
were separated by filtration. 
 
Preparation of crystals of compound 1 with  
PEG-4000 (1C) 
A 1:1 mixture (weight by weight, w/w) of 
compound 1 and PEG 4000 were ground manually in 
an agate mortar at room temperature for 5 min 
together with the addition of a few drops of acetone. 
However, upon removal of the solvent, the 
components remained as mixtures. Subsequently, a 
1:1 mixture (w/w) of compound 1 and PEG 4000 
were taken in a round bottomed flask and dissolved in 
30 mL of acetone under constant stirring at 50 °C. 
The solution was filtered and cooled to room 
temperature. Crystals were obtained after two days 
which were filtered and dried in a desiccator over 
silica gel at room temperature. 
Similar method was followed for preparation of 




 In vivo efficacy studies of compound (1) and its 
modified crystals based on their effect on inhibition of 
fasting induced food intake in C57 mice The animals 
(C57 mice) were trained for fasting induced food 
intake. In this procedure, they were allowed access to 
chow diet from 11 a.m. to 3 p.m. every day, and 
fasted for rest 20 hours of the day. They were 
randomized based on their intake, when their daily 
four hour intake was consistent for two consecutive 
days. On the day of experiment, the mice were 
administered the test compounds formulated in saline 
by intraperitoneal route. The food intake was 
measured for next four hours, and for subsequent 20 
hours. The percent inhibition in the food intake was 
calculated based on the vehicle control group. 
 
Results and Discussion 
The compound 1 was synthesized by the reported 
procedure and characterized11. The polymer and 
compound 1 adducts were synthesized and subjected 
to various characterization and analysis such as 
crystallinity, differences in their melting points  
with respect to pure compound, changes in their 
crystal morphology using polarizing microscope  
and SEM of the modified crystals were compared 
with the parent compound 1 and efficacies of the 
modified crystals were compared with pure 
compound. Effort were also directed to understand the 
role of polymeric additives on crystal morphology and 
packing of the compound 1. 
 
Single crystal X-ray study of 1 
The compound 1 was crystallized out from acetone 
under slow solvent evaporation method at room 
temperature and it crystallized in triclinic crystal 
system with space group P-1. The asymmetric unit 
contains one molecule of compound 1, which 
displayed multiple non-covalent interactions, such as 
Cl….Cl, C-H…O, etc., leading to three dimensional 
network. One of the prominent halogen….halogen 
interactions in compound 1 formed 0-D network 
(zero-dimensional) (Figure 3A) and the another 
Cl…Cl interaction extended the overall packing of 1 
to 1D (one-dimensional) (Figure 3B). The number of 
secondary interactions such as C-H…O, van der 
Waals forces, extended the packing of 1 to 3-D(three 
dimensional). (See supporting information for 
detailed crystallographic data Table S1). 
 
IR study 
IR studies were carried out to establish the nature 
of weak interactions (hydrogen bonding or halogen 
bonding) between compound 1 and polymer adducts 
(1C-1E). IR frequency of aromatic C-Cl bond (strong 
peak at 819 cm-1) of 1 changed to bifurcated peak, i.e. 
817 and 812 cm-1 in certain polymer adducts namely 
 
 
Figure 3 — (A) Intermolecular halogen bonding leading to zero-
dimensional network of 1 (B) One dimensional halogen bonded 
network of 1 




(1C, 1D and 1E). The slight change in position and 
nature of IR frequency is interpreted as the formation 
of hydrogen/halogen bonded network.24 However, no 
significant change in C=O frequency of amide 
functional group in 1 and 1A-1E polymer adducts 
were noticed. The formation of weak non-covalent 
bonds between the chlorine atoms of compounds 1 
with the polymers, leading to change in crystalline 
packing as well as morphological change especially in 
polymer adducts 1C, 1D and 1E [see supporting 
information, Figure S1] is being proposed, based on 
the following observations. 
 
Morphology 
The crystals of 1 appeared to be well defined 
rectangular in shape with smooth surface under 
microscope [See supporting information Figure 
S2(A)]. Surprisingly, no well-defined crystalline 
substance was obtained using PEG 200 as additive 
(1A). When compound 1 was crystallized with PEG 
300 (1B), no significant change in morphology was 
observed under polarizing microscope [See 
supporting information Figure S2(B)]. Surprisingly, 
crystallization of 1 with each of PEG 4000 (1C), PVA 
(1D) and PVP K-30 (1E), changed the crystal 
morphologies significantly i.e. from smooth tubular 
architecture to rough irregular shaped crystals [See 
supporting information Figures S2(C) to S2(E)].  
To visualize the morphologies of the crystals formed 
in the presence of various polymeric additives 
thoroughly, SEM analysis was carried out. SEM 
images of 1 and 1B-1E corroborates well with the 
polarizing microscope studies. Crystals of 1 obtained 
in the presence of PEG 300 polymer additive 
[Figure 4(B)] exhibited similar morphology as pure 
form of compound 1 in SEM analysis [Figure 4(A)], 
while, use of PEG 4000, PVA and PVP K-30, 
significantly changed the morphology of the crystals 
[Figure 4C–E]. These studies suggest that the 
molecular weight of polymer (PEG polymeric 
additives) as well as the functional groups in the 
polymer additive (PVA and PVP K30) may play a 
role in modifying the crystal morphology of 1. 
 
Powder X-ray diffraction study 
In order to understand whether there is any change 
in crystalline packing of compound 1 in presence and 
absence of polymeric additives powder x- ray 
diffractogram (PXRD) of 1 and the polymeric adducts 
(1C-1E) were recorded. The XRD pattern of crystalline 
1 is provided in Figure 5A. There was no change in the 
XRD pattern when PEG 300 was used. This further 
confirms that PEG 300 did not change the morphology 
or the crystalline structure of compound 1. 
However, with each of PEG-4000, PVA and 
PVPK-30, the XRD pattern changed substantially 
from the PXRD pattern of 1 [Figure 5(C) to 
Figure 5(E)] (see supporting information Table S2 for 
a comparison of the peaks with highest intensities for 
compounds 1 and the polymer adducts 1C-1E]. This 
clearly indicates that these polymers were able to 
modify both the morphologies as well as the 
crystalline packing of compound 1. 
 
Thermal Analysis 
The DSC thermogram of compound 1 displayed a 
sharp peak at 199.93 °C, with an onset temperature of 
198 °C [See supporting information figure S3(A)] . 
The DSC thermogram using PEG-300 did not show 
any difference from that of 1. The DSC thermogram 
of the crystal obtained with PEG-4000 showed one 
sharp endotherm at 61.81 °C and a second small peak 
at 197.6 °C [See supporting information figure 
S3(B)]. The former peak clearly indicates that the 
PEG-4000 was loosely bound to the compound 1, 
thereby providing the endothermic peak close to its 
melting point (54-58 °C). Coupled with the fact that 
 
 
Figure 4 — SEM images of crystal morphology of (A) 1, (B) 1B
(PEG-300), (C) 1C (PEG 4000), (D) 1D (PVA) and (E) 1E
(PVP K-30) 




the XRD pattern has changed, one can conclude that 
the PEG-4000 may have formed a co-crystal with the 
compound 1. The second endotherm at 197.6 °C also 
supports the formation of a co-crystal. 
Interestingly, the DSC thermogram of the crystals 
obtained using PVA and PVPK-30, showed a  
single endotherm peak at 199.32 and 199.19 °C 
respectively [See supporting information figureS2]. 
This clearly rules out the formation of any co-crystal. 
The formation of alternate polymorphic forms  




Saturated solubility studies of the samples  
were performed in water at room temperature for  
24 hours. The solubility of compound 1 in water did 
not change when crystallized from different organic 
polymers. Therefore, for the compound 1, making  
of the amorphous form is the only way to improve  
its solubility in water. Interestingly, polymers  
were able to solubilize the compound 1. These 
polymers being of the GRAS family, such solutions 
can be used for conducting in vivo studies and crystal 
adducts so obtained could be used for further 
development studies. 
 
In vivo efficacy study 
The effect of the modified compounds of (1) was 
studied on inhibition of fasting induced food intake in 
C57 mice after single intraperitoneal dose at 30mg/kg. 
The results are provided in Table I. 
The observed results (mean ± SD, n=5) indicate 
that there is reduction in the fasting induced food 
intake after the test compound administration. The 
reduction was prominent for the first four hours. 
 
 
Figure 5 — Powder X-ray diffractogram of (a) 1 , (b) 1B (PEG-300) , (c) 1C (PEG-4000), (d) 1D (PVA), (e) 1E (PVP K-30) 
 




However, there was no significant difference amongst 
the different treatment groups. 
 
Conclusions 
Crystal structure of 1 showed presence of halogen 
bonds leading to 1D network and understandably, the 
halogen bonds will play prominent role in the 
physico-chemical properties of 1. GRAS polymeric 
additives, such as PEG, PVA, PVP K30, with 
functional groups capable of forming weak non-
covalent interactions with 1 were selected and 
successfully used to carry out morphological  
and polymorphic changes to 1. The molecular  
weight of the polymer, in case of the PEG class of 
polymers, was found to be playing a role in changing 
the morphology and crystalline packing of 1. 
Thus,PEG-200 and PEG 300 were found to be  
less effective as compared with PEG-4000. 
Understandably, the high molecular weight polymers 
can adsorb better and cover a large surface area of the 
compound 1 to bring a significant morphological 
change. Polymeric crystal habit modifiers, especially 
PEG-4000, PVA and PVP K30, were also capable of 
forming new polymeric forms of 1. Surprisingly, such 
change in crystal forms of 1 did not have any effect 
on either the solubility or the in vivo efficacy of the 
modified compounds. Such polymers may therefore 
be used to change the crystalline forms of the 
compounds without affecting the biological properties 
of the compound. IR spectra of compound 1 in 
presence and absence of polymeric additives 
displayed changes in C-Cl stretching frequency from 
strong peak (pure form) to bifurcated peaks 
(polymeric additives, 1C-1E) establishing the change 
in halogen bonding pattern. The formation of new 
polymorphic form of 1 in presence of polymeric 
additives was further established with the help of 
PXRD and DSC analysis. The present study opens a 
window of opportunity to tune the morphology, 
crystal packing without effecting the efficacy of an 
API using GRAS polymeric additives. 
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